2 View gallery <\/p>\n
![\"\u05dc\u05d9\u05de\u05e4\u05d5\u05de\u05d4](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/12\/SJYijpfGbg_0_0_1000_563_0_x-large.jpg\" "\\"Innovative")
<\/a><\/p>\n
Innovative lymphoma treatment yields impressive 100% survival rate <\/p>\n
(Photo: Shutterstock)<\/p>\n
The study also found that only 4% of patients required additional radiation therapy \u2014 a significantly lower rate than in the past. Most side effects were manageable, and the one-year survival rate reached 100%. The findings place Israel at the forefront of global lymphoma treatment and highlight how collaboration between public medical centers can lead to meaningful breakthroughs for patients.<\/p>\n
Hodgkin lymphoma is a malignancy of the lymphatic system. It accounts for about 10% of all lymphoma cases and is especially common among young adults. The disease typically presents with swollen lymph nodes and may also include so-called \u201cB symptoms\u201d such as fever, night sweats and weight loss. Diagnosis is made through a biopsy of an affected lymph node, and disease staging is done using a PET-CT scan. Treatment is tailored to the stage of the disease and generally includes a combination of chemotherapy and biological drugs, sometimes with the addition of radiation. It is considered a highly curable cancer, with cure rates exceeding 85%, and even in cases of relapse, effective treatment options exist.<\/p>\n
She added, \u201cOur study brings Israeli experience to the global stage for the first time and presents a unified, comprehensive picture from all of the country\u2019s medical centers. Presenting the study at the ASH conference with a broad Israeli team highlights Israel\u2019s leading role in the field of hematology.\u201d<\/p>\n When research meets real life<\/p>\n Dr. Roy Vitkon, a senior physician specializing in internal medicine and hematology at Ichilov Medical Center, noted that in 2024, the journal The Lancet published a large German study<\/a> introducing a new first-line treatment protocol for advanced Hodgkin lymphoma. \u201cThe protocol raised high expectations \u2014 and indeed, the results were particularly impressive. The researchers showed it was possible to achieve cure rates of nearly 100%.\u201d According to Dr. Vitkon, the uniqueness of the new protocol lies not only in its high efficacy but also in its side effect profile. \u201cThe previous protocol used until then was associated with very severe side effects. The new one showed not only high effectiveness but also much better tolerability, making it suitable for the majority of patients.\u201d<\/p>\n As is often the case, there can be a gap between the outcomes of controlled clinical trials and what happens in real-world practice. For that reason, studies known as Real World Data are typically conducted following major publications, collecting data from everyday clinical settings to determine whether the impressive results hold up in practice.<\/p>\n![\"\u05d3"\u05e8](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/12\/rJp8cb4fWg_0_0_1200_1600_0_medium.jpg\" "\\"Dr.")
Dr. Tzofia LevyPhoto: CourtesyThe study was led by Dr. Zvi Forgas, a senior physician in the Hematology Institute at Soroka Medical Center<\/a>, and Dr. Tzofia Levy, a senior physician in the Hematology Division at Rambam Health Care Campus, who is also presenting the findings at the conference. \u201cThe new treatment protocol represents a true revolution in Hodgkin lymphoma care,\u201d she said. \u201cIt enables patients to achieve full disease control \u2014 and in some cases, even a cure \u2014 in just nine weeks. In most patients, signs of the cancer disappeared early in the process, and by the end of treatment, there was little to no evidence of disease.\u201d<\/p>\n![\"\u05d3"\u05e8](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/12\/HJbuLazGbe_0_32_1066_1422_0_medium.jpg\" "\\"Dr.")
Dr. Roy VitkonPhoto: The American Society of Hematology (ASH)<\/p>\n
![\"\u05dc\u05d9\u05de\u05e4\u05d5\u05de\u05d4](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/12\/rJQ2dpzMWl_0_34_1000_563_0_x-large.jpg\" "\\"A")
<\/a>